Stockreport

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Sensei Biotherapeutics, Inc.  (SNSE) 
PDF - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity -  - Pharmacokinetic and safety profile validate conditionally activ [Read more]